Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Common stock, $.01 par value per share
-
Shares outstanding
-
46,791,479
-
Total 13F shares
-
56,558,011
-
Share change
-
+530,747
-
Total reported value
-
$4,415,683,452
-
Put/Call ratio
-
88%
-
Price per share
-
$78.08
-
Number of holders
-
305
-
Value change
-
+$40,389,204
-
Number of buys
-
159
-
Number of sells
-
130
Institutional Holders of HAEMONETICS CORP - Common stock, $.01 par value per share (HAE) as of Q4 2024
As of 31 Dec 2024,
HAEMONETICS CORP - Common stock, $.01 par value per share (HAE) was held by
305 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
56,558,011 shares.
The largest 10 holders included
BlackRock, Inc., VANGUARD GROUP INC, NEUBERGER BERMAN GROUP LLC, Capital Research Global Investors, WELLINGTON MANAGEMENT GROUP LLP, T. Rowe Price Investment Management, Inc., STATE STREET CORP, Thrivent Financial for Lutherans, GEODE CAPITAL MANAGEMENT, LLC, and ROYCE & ASSOCIATES LP.
This page lists
307
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.